

Hemovigilance Module Adverse Reaction Transfusion Associated Graft vs. Host Disease

*Required for saving						
*Facility ID#: NHSN Adv	verse Reaction #	:				
Patient Information						
*Patient ID:	*Gender: M	F Other	*Date of Birth://			
Sex at Birth: M F Unknown			Gender Identity (Specify):			
			Male			
			Female Mala ta famala transgandar			
			Male-to-female transgender Female-to-male transgender			
			Identifies as non-conforming			
			Other			
			Asked but unknown			
Social Security #:	Secondary ID:					
Last Name:	First Name:	Middle Name:				
Ethnicity (Specify):			elect all that apply):			
Hispanic or Latino		American Indian or	Alaska Native			
Not Hispanic or Latino Unknown		Asian Black or African An	herican			
Declined to respond		Middle Eastern or N				
		Native Hawaiian or	Pacific Islander			
		White Unknown				
		Declined to respond				
			Interpreter Needed: Yes No			
Preferred Language (Specify):			Declined to Respond Unknown			
*Blood Group: A- A+ B	- B+ AB-	- AB+ O				
Transitional ABO / F		nsitional ABO / Rh -	Transitional ABO / Transitional Rh			
	B/Transitional					
Rh Rh	Di Transitional	Group O/Trans	itional Rh Group AB/Transitional Rh			
Patient Medical History						
List the patient's admitting diagnosi	s. (Use ICD-10 E	Diagnostic codes/de	scriptions)			
Code: [Description:					
Code: [Description:					
Code: Description:						
List the patient's underlying indication for transfusion. (Use ICD-10 Diagnostic codes/descriptions)						
Code: [Description:					
Code: [Description:					

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). CDC 57.316 Rev. 3, v9.2

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666).



Code:	Description:	
List the patient's comorbid conditions at the time of the transfusion related to the adverse reaction. (Use ICD-10 Diagnostic codes/descriptions)		
Code:	Description:	
Code:	Description:	
Code:	Description:	



	nedical procedure including past procedures and procedures to be UNKNOWN nt hospital or outpatient stay. (Use ICD-10 Procedure NONE
Code:	Description:
Code:	
Code:	Description:
Additional Information	
Transfusion History	
Has the patient received a Blood Product:	WB RBC Platelet Plasma Cryoprecipitate Granulocyte
	e reaction transfusion-related?
Type of transfusion adve	n about the transfusion adverse reaction. rse reaction: Allergic AHTR DHTR DSTR FNHTR PTP TACO TAD TA-GVHD TRALI UNKNOWN fy
Reaction Details	
*Date reaction occurred:	// *Time reaction occurred:: Time unknown
*Facility location where pati	ent was transfused:
Is this reaction associated with	h an incident? Yes No If Yes, Incident #:
Investigation Results	
* Transfusion associated	l graft vs. host disease (TA-GVHD)
*Case Definition	
Did patient receive non-in	radiated blood product(s) in the two months preceding the reaction?
Check all that occurred v	within 2 days to 6 weeks after cessation of transfusion:
Clinical syndrome	
Liver dysfunc	e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia
	c rash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation.
Check all that apply: Characteristic histol Biopsy negative or	logical appearance of skin or liver biopsy. not done.
Other signs and symptoms	
Other signs and symptoms	: <u>(check all that apply)</u>
Generalized:	: <u>(check all that apply)</u> Chills/rigors Nausea/vomiting



٦

Hemolysis/Hemorrhage:	Disseminated intravascular coagulation Hemoglobinemia Positive antibody screen					
Pain:	Abdominal pain	Back pain	Flank pain			
Renal:	Hematuria	Hemoglobinuria	Oliguria			
Respiratory:	Bronchospasm	Cough	Shortness of breath			
Other: (specify)						
*Severity						
Did the patient receive or	experience any of the fo	ollowing?				
No treatment requ		Symptomatic trea	atment only			
	Icuding prolonged hospit		Life-threatening reaction			
Disability and/or ir	•••••		aly or birth defect(s) of the fetus			
	nportant conditions	Death	Unknown or not stated			
*Imputability						
Which best describes the	relationship between the	e transfusion and the	reaction?			
No other alternative	e diagnoses.					
Other potential cau	uses are present (e.g., ste	em cell transplantatio	n).			
Alternative explana	ations are more likely (e.ç	g., solid organ transpl	antation).			
Evidence is clearly	in favor of a cause other	than the transfusion,	but transfusion cannot be excluded.			
There is conclusive	evidence beyond reasor	nable doubt of a caus	e other than the transfusion			
The relationship be	tween the adverse reacti	ion and the transfusio	n is unknown or not stated.			
Did the transfusion occur	at your facility?	YES NO				
WBC chimerism:	WBC chimerism prese	nt WBC cl	nimerism not present or not done			
Module-generated Desig	Inations					
NOTE: Designations for case application based on respons			tomatically assigned in the NHSN ection above.			
*Do you agree with the		-	YES NO			
^Please indicate your de	-					
-			YES NO			
*Do you agree with the ^Please indicate your de			YES NO			
-	-					
*Do you agree with the		on?	YES NO			
^Please indicate your de	signation					
Patient Treatment						
Did the patient receive trea	tment for the transfusion	reaction?	YES NO UNKNOWN			
If yes, select treatment(s):						
Medication (Select the type of medication)						
Antipyretics Antihistamines Inotropes/Vasopressors Bronchodilator Diuretics						
Intravenous						
Immunoglobulin Intravenous steroids Corticosteroids Antibiotics						
Antithymocyte globulin Cyclosporin Other						
Page 4 of 6						

NATIONAL HEAL SAFETY NETV	SN THCARE VORK						OMB No. Exp. Date:	n Approved 0920-0666 12/31/2026 lc.gov/nhsn
Volu	ume resuscitation (Intr	avenous colloid	s or cr	ystalloids)				
Res	piratory support <i>(Sele</i> Mechanical ventilati		••••	e ventilation	Oxyger	ı		
						I		
	al replacement therap	Peritoneal			no-Venous Hem	ofiltration		
Phle	ebotomy							
Othe	er Specify:							
Outcome				-	7	- 「		
*Outcome: Date of		lajor or long-terr	n sequ	ielae	Minor or no se	equelae	Not detern	nined
	ecipient died, relation	/ shin of transfus	ion to	death:				
	Definite Probabl	·	_	Doubtful	Ruled Ou	t 🗌	Not determine	ed
Cause	of death:							
Was an	autopsy performed?	Yes	No)				
Component	Details							
-	cular unit implicated	d in (i.e., respo	onsibl	e for) the a	dverse	Yes	No	N/A
		A		number	41 8 - 14			
Transfusion Start and End Date/Time	*Component code (check system used)			lired for *Unit ion and expiration 1) Date/Time		*Blood group of unit		Implicat ed Unit?
All								
/ /	ISBT-128							
:	Codabar	Entire unit				A	A+B-	
		Partial unit						Y
//		mL					B- AB+	
:	ISBT-128				·	0-	0+ N/A	
//	Codabar	Entire unit				A-	A+ B-	
		Partial unit						N
//		mL	<u> </u>			B+A	B- AB+	
<u> </u>					::	0-	O+N/A	
Custom Field	ls							
Label				Label				
Comments								
Comments								

